1. A myelodysplastic neoplasm with del(5q) treated with luspatercept uncovers unexplored mechanisms of action for the drug.
- Author
-
Patsialos, Iraklis, Kontandreopoulou, Christina‐Nefeli, Vlachopoulou, Dimitra, Stafylidis, Christos, Syriopoulou, Stavroula, Kalala, Fani, Anastasopoulou, Amalia, Mantzourani, Marina, and Diamantopoulos, Panagiotis
- Subjects
TRANSFORMING growth factors-beta ,GROWTH differentiation factors ,RED blood cell transfusion ,REGULATORY T cells ,ACUTE myeloid leukemia ,AZACITIDINE ,SICKLE cell trait - Abstract
The article in the British Journal of Haematology discusses a case study of a 79-year-old man with myelodysplastic syndrome (MDS) and a 5q deletion who was effectively treated with luspatercept after failing to respond to other treatments. The patient showed significant improvements in blood counts and bone marrow characteristics after luspatercept treatment, even after discontinuation. The study highlights the potential mechanisms of action of luspatercept beyond late-stage erythropoiesis enhancement, suggesting broader effects on hematopoiesis and inflammation. The findings suggest a need for further research on the complex actions of luspatercept in MDS patients with specific genetic abnormalities. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF